Physician profile
Peter A Dabrowski
NPI 1447260229
$3,538.62
in general payments reported to CMS, 2019-2025
22 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $888 · 2021: $590 · 2022: $342 · 2023: $112 · 2024: $190 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $855.55 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $830.01 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $454.32 | 2019-2024 | Breztri |
| Lilly USA, LLC | $309.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $234.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.73 | 2019-2024 | Trintellix |
| Arbor Pharmaceuticals, INC. | $82.26 | 2019-2022 | |
| Abbvie INC. | $71.05 | 2021-2023 | Vraylar |
| Amarin Pharma, INC. | $63.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $60.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.39 | 2022-2024 | |
| Exact Sciences Corporation | $44.29 | 2023-2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $44.26 | 2019 | |
| Allergan, INC. | $41.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $39.88 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.62 | 2020-2024 | Shingrix |
| Abbott Laboratories | $20.85 | 2022 | |
| Currax Pharmaceuticals LLC | $17.24 | 2025 | Contrave |
| Azurity Pharmaceuticals, INC. | $14.39 | 2023 | Edarbi |
| Sanofi-Aventis U.S. LLC | $13.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dabrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.